Ibuprofen/Probiotic Study Receive $1200 — $1200

Non-Steroidal-Anti-Inflammatory Drugs (NSAIDs), such as Ibuprofen, are commonly used worldwide, both as prescription-only medicines and as “over-the-counter” medications. They are often used in the treatment of many common pain-related conditions, including headaches and menstrual pain, and for long-term treatment of chronic inflammatory diseases, including osteoarthritis and rheumatoid arthritis. Long-term use of low-dose NSAIDS are also recommended and prescribed for their heart-protecting properties.

However, low dose use of NSAIDS, such as ibuprofen, is associated with damage to the stomach and intestines.

Live bacteria formulated as probiotics may offer a safe alternative to prevent negative side effects of NSAIDS, such as ibuprofen. Probiotic bacteria have been demonstrated to have possible healing effects against intestinal inflammation among long-term ibuprofen users.

The goal of this study is to explore the ability of a probiotic to reduce and/or reverse ibuprofen-induced small intestinal damage and GI symptoms in healthy volunteers.

The study includes a run-in period lasting up to two-weeks, followed by a six-week intervention period where a dose of probiotic or placebo is taken daily, along with ibuprofen. The study Involves a screening visit and 6 subsequent visits to the study site.

At each of the 6 visits, we will measure the ibuprofen damage to your intestine using Video Capsule Endoscopy (VCE). Capsule endoscopy uses a tiny wireless camera which sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist. The capsule is excreted after about 8-12 hours We will also collect some blood and stool samples as well as some demographic and general health data at each visit.

You will receive $1200 for your time upon completion of the trial.

You will receive $1200 for your time upon completion of the trial.